Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1954 2
1956 2
1958 1
1959 4
1960 2
1961 4
1962 1
1963 2
1964 2
1965 1
1966 5
1967 1
1977 1
1980 1
1986 1
1990 1
1995 1
1998 1
1999 2
2003 1
2005 1
2006 1
2007 1
2008 1
2009 2
2010 4
2011 7
2012 47
2013 43
2014 34
2015 38
2016 33
2017 29
2018 19
2019 26
2020 44
2021 37
2022 30
2023 29
2024 29
2025 26

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

406 results

Results by year

Filters applied: . Clear all
Page 1
Adjuvant Pembrolizumab after Nephrectomy in Renal-Cell Carcinoma.
Choueiri TK, Tomczak P, Park SH, Venugopal B, Ferguson T, Chang YH, Hajek J, Symeonides SN, Lee JL, Sarwar N, Thiery-Vuillemin A, Gross-Goupil M, Mahave M, Haas NB, Sawrycki P, Gurney H, Chevreau C, Melichar B, Kopyltsov E, Alva A, Burke JM, Doshi G, Topart D, Oudard S, Hammers H, Kitamura H, Bedke J, Perini RF, Zhang P, Imai K, Willemann-Rogerio J, Quinn DI, Powles T; KEYNOTE-564 Investigators. Choueiri TK, et al. N Engl J Med. 2021 Aug 19;385(8):683-694. doi: 10.1056/NEJMoa2106391. N Engl J Med. 2021. PMID: 34407342 Free article. Clinical Trial.
Overall Survival with Adjuvant Pembrolizumab in Renal-Cell Carcinoma.
Choueiri TK, Tomczak P, Park SH, Venugopal B, Ferguson T, Symeonides SN, Hajek J, Chang YH, Lee JL, Sarwar N, Haas NB, Gurney H, Sawrycki P, Mahave M, Gross-Goupil M, Zhang T, Burke JM, Doshi G, Melichar B, Kopyltsov E, Alva A, Oudard S, Topart D, Hammers H, Kitamura H, McDermott DF, Silva A, Winquist E, Cornell J, Elfiky A, Burgents JE, Perini RF, Powles T; KEYNOTE-564 Investigators. Choueiri TK, et al. N Engl J Med. 2024 Apr 18;390(15):1359-1371. doi: 10.1056/NEJMoa2312695. N Engl J Med. 2024. PMID: 38631003 Clinical Trial.
Pembrolizumab versus placebo as post-nephrectomy adjuvant therapy for clear cell renal cell carcinoma (KEYNOTE-564): 30-month follow-up analysis of a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.
Powles T, Tomczak P, Park SH, Venugopal B, Ferguson T, Symeonides SN, Hajek J, Gurney H, Chang YH, Lee JL, Sarwar N, Thiery-Vuillemin A, Gross-Goupil M, Mahave M, Haas NB, Sawrycki P, Burgents JE, Xu L, Imai K, Quinn DI, Choueiri TK; KEYNOTE-564 Investigators. Powles T, et al. Lancet Oncol. 2022 Sep;23(9):1133-1144. doi: 10.1016/S1470-2045(22)00487-9. Lancet Oncol. 2022. PMID: 36055304 Free article. Clinical Trial.
European Association of Urology Guidelines on Muscle-invasive and Metastatic Bladder Cancer: Summary of the 2023 Guidelines.
Alfred Witjes J, Max Bruins H, Carrión A, Cathomas R, Compérat E, Efstathiou JA, Fietkau R, Gakis G, Lorch A, Martini A, Mertens LS, Meijer RP, Milowsky MI, Neuzillet Y, Panebianco V, Redlef J, Rink M, Rouanne M, Thalmann GN, Sæbjørnsen S, Veskimäe E, van der Heijden AG. Alfred Witjes J, et al. Among authors: rink m. Eur Urol. 2024 Jan;85(1):17-31. doi: 10.1016/j.eururo.2023.08.016. Epub 2023 Oct 17. Eur Urol. 2024. PMID: 37858453 Review.
Cabozantinib versus Everolimus in Advanced Renal-Cell Carcinoma.
Choueiri TK, Escudier B, Powles T, Mainwaring PN, Rini BI, Donskov F, Hammers H, Hutson TE, Lee JL, Peltola K, Roth BJ, Bjarnason GA, Géczi L, Keam B, Maroto P, Heng DY, Schmidinger M, Kantoff PW, Borgman-Hagey A, Hessel C, Scheffold C, Schwab GM, Tannir NM, Motzer RJ; METEOR Investigators. Choueiri TK, et al. N Engl J Med. 2015 Nov 5;373(19):1814-23. doi: 10.1056/NEJMoa1510016. Epub 2015 Sep 25. N Engl J Med. 2015. PMID: 26406150 Free PMC article. Clinical Trial.
Pathomics in urology.
Schuettfort VM, Pradere B, Rink M, Comperat E, Shariat SF. Schuettfort VM, et al. Among authors: rink m. Curr Opin Urol. 2020 Nov;30(6):823-831. doi: 10.1097/MOU.0000000000000813. Curr Opin Urol. 2020. PMID: 32881725 Review.
Evaluation of Gremlin-1 as a therapeutic target in metabolic dysfunction-associated steatohepatitis.
Horn P, Norlin J, Almholt K, Viuff BM, Galsgaard ED, Hald A, Zosel F, Demuth H, Poulsen S, Norby PL, Rasch MG, Vyberg M, Fleckner J, Werge MP, Gluud LL, Rink MR, Shepherd E, Northall E, Lalor PF, Weston CJ, Fog-Tonnesen M, Newsome PN. Horn P, et al. Among authors: rink mr. Elife. 2024 Oct 3;13:RP95185. doi: 10.7554/eLife.95185. Elife. 2024. PMID: 39361025 Free PMC article.
European Association of Urology Guidelines on Muscle-invasive and Metastatic Bladder Cancer: Summary of the 2025 Guidelines.
van der Heijden AG, Bruins HM, Carrion A, Cathomas R, Compérat E, Dimitropoulos K, Efstathiou JA, Fietkau R, Kailavasan M, Lorch A, Martini A, Mertens LS, Meijer RP, Mariappan P, Milowsky MI, Neuzillet Y, Panebianco V, Sæbjørnsen S, Smith EJ, Thalmann GN, Rink M. van der Heijden AG, et al. Among authors: rink m. Eur Urol. 2025 May;87(5):582-600. doi: 10.1016/j.eururo.2025.02.019. Epub 2025 Mar 20. Eur Urol. 2025. PMID: 40118736
Prognostic Impact and Spatial Interplay of Immune Cells in Urothelial Cancer.
Debatin NF, Bady E, Mandelkow T, Huang Z, Lurati MCJ, Raedler JB, Müller JH, Vettorazzi E, Plage H, Samtleben H, Klatte T, Hofbauer S, Elezkurtaj S, Furlano K, Weinberger S, Giacomo Bruch P, Horst D, Roßner F, Schallenberg S, Marx AH, Fisch M, Rink M, Slojewski M, Kaczmarek K, Ecke TH, Hallmann S, Koch S, Adamini N, Lennartz M, Minner S, Simon R, Sauter G, Zecha H, Schlomm T, Blessin NC. Debatin NF, et al. Among authors: rink m. Eur Urol. 2024 Jul;86(1):42-51. doi: 10.1016/j.eururo.2024.01.023. Epub 2024 Feb 21. Eur Urol. 2024. PMID: 38383257 Free article.
406 results